SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ... Science 355 (6320), 84-88, 2017 | 910 | 2017 |
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ... Nature 571 (7765), 408-412, 2019 | 207 | 2019 |
Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer Z Zhang, WR Karthaus, YS Lee, VR Gao, C Wu, JW Russo, M Liu, ... Cancer Cell 38 (2), 279-296. e9, 2020 | 177 | 2020 |
Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones D Liang, Y Feng, F Zandkarimi, H Wang, Z Zhang, J Kim, Y Cai, W Gu, ... Cell 186 (13), 2748-2764. e22, 2023 | 126 | 2023 |
Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation Z Zhang, C Zhou, X Li, SD Barnes, S Deng, E Hoover, CC Chen, YS Lee, ... Cancer cell 37 (4), 584-598. e11, 2020 | 117 | 2020 |
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis R Bose, WR Karthaus, J Armenia, W Abida, PJ Iaquinta, Z Zhang, ... Nature 546 (7660), 671-675, 2017 | 81 | 2017 |
Macrophages promote anti-androgen resistance in prostate cancer bone disease XF Li, C Selli, HL Zhou, J Cao, S Wu, RY Ma, Y Lu, CB Zhang, B Xun, ... Journal of Experimental Medicine 220 (4), e20221007, 2023 | 23 | 2023 |
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon D Gao, Y Zhan, W Di, AR Moore, JJ Sher, Y Guan, S Wang, Z Zhang, ... PLoS One 11 (8), e0161084, 2016 | 23 | 2016 |
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer X Li, Y Wang, S Deng, G Zhu, C Wang, NA Johnson, Z Zhang, CR Tirado, ... Cancer cell 41 (8), 1427-1449. e12, 2023 | 17 | 2023 |
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers N Mao, Z Zhang, YS Lee, D Choi, AA Rivera, D Li, C Lee, S Haywood, ... Nature Communications 12 (1), 5053, 2021 | 16 | 2021 |
A SMAD4‐modulated gene profile predicts disease‐free survival in stage II and III colorectal cancer BC Szeglin, C Wu, MR Marco, HS Park, Z Zhang, B Zhang, ... Cancer Reports 5 (1), e1423, 2022 | 13 | 2022 |
Oncogenic ERG represses PI3K signaling through downregulation of IRS2 N Mao, D Gao, W Hu, S Gadal, H Hieronymus, S Wang, YS Lee, ... Cancer research 80 (7), 1428-1437, 2020 | 11 | 2020 |
ROLE OF TUMOR MICROENVIRONMENT DERIVED NRG1 IN ANDROGEN RESISTANCE: IMPLICATIONS FOR A NOVEL PROSTATE CANCER TREATMENT STRATEGY B Shinder, N Mao, N Salsabeel, Z Zhang, CL Sawyers, BS Carver Urologic Oncology: Seminars and Original Investigations 42, S86-S87, 2024 | | 2024 |
Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer E Lee, Z Zhang, CC Chen, D Choi, ACA Rivera, E Linton, Y Ho, J Love, ... bioRxiv, 2024.03. 18.585532, 2024 | | 2024 |
Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity Z Zhang, C Zhou, X Li, S Barnes, S Deng, E Hoover, CC Chen, YS Lee, ... Cancer Research 80 (16_Supplement), NG06-NG06, 2020 | | 2020 |